. "European Journal of Haematology" . "7"^^ . "Smolej, L." . "13"^^ . . "10.1111/ejh.12106" . . . "Brychtov\u00E1, Yvona" . "The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab" . "Trbu\u0161ek, Martin" . . . "Panovsk\u00E1, Anna" . . . . "RIV/00216224:14740/13:00065583!RIV14-MZ0-14740___" . "DK - D\u00E1nsk\u00E9 kr\u00E1lovstv\u00ED" . "[D3C18ED7A151]" . . . "The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab"@en . . "chronic lymhocytic leukemia; FRC chemoimmunotherapy; relapse; survival"@en . . "Background There is minimal data about the efficacy of subsequent therapy in patients with relapse after FCR (fludarabine, cyclophosphamide, rituximab) chemoimmunotherapy. Methods We retrospectively analyzed the outcomes of 119 patients who relapsed after standard-dose FCR. The patient cohort consisted of patients who relapsed after FCR administered as first-line therapy (Group 1, n=63) and patients relapsing after FCR administered in second/subsequent line; (Group 2, n=56). Results Basic parameters (age, clinical stage, cytogenetics, molecular genetics) did not differ significantly between these subgroups. Likewise, median progression-free survival (PFS) was not considerably different after FCR (18.6 vs. 14.7 months). Subsequent therapy for relapsed disease included FCR retreatment, R-CHOP, alemtuzumab, or rituximab plus high-dose dexamethasone. Overall response rates for the two groups did not significantly differ (59% vs. 44%)."@en . "The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab"@en . . "The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab" . "Lys\u00E1k, D." . "I, P(ED1.1.00/02.0068), P(EE2.3.20.0045), P(FR-TI2/254), P(NT13412), P(NT13493), P(NT13519)" . . "Posp\u00ED\u0161ilov\u00E1, \u0160\u00E1rka" . . "90" . . . . "Vod\u00E1rek, P." . . . "RIV/00216224:14740/13:00065583" . . "Background There is minimal data about the efficacy of subsequent therapy in patients with relapse after FCR (fludarabine, cyclophosphamide, rituximab) chemoimmunotherapy. Methods We retrospectively analyzed the outcomes of 119 patients who relapsed after standard-dose FCR. The patient cohort consisted of patients who relapsed after FCR administered as first-line therapy (Group 1, n=63) and patients relapsing after FCR administered in second/subsequent line; (Group 2, n=56). Results Basic parameters (age, clinical stage, cytogenetics, molecular genetics) did not differ significantly between these subgroups. Likewise, median progression-free survival (PFS) was not considerably different after FCR (18.6 vs. 14.7 months). Subsequent therapy for relapsed disease included FCR retreatment, R-CHOP, alemtuzumab, or rituximab plus high-dose dexamethasone. Overall response rates for the two groups did not significantly differ (59% vs. 44%)." . . "14740" . . . "Doubek, Michael" . . "Moty\u010Dkov\u00E1, M." . . "0902-4441" . . "\u0160imkovi\u010D, M." . "Mal\u010D\u00EDkov\u00E1, Jitka" . "Mayer, Ji\u0159\u00ED" . . "8"^^ . "6" . "000319143100003" . . "Lindtnerov\u00E1, Michaela" . "94890" .